Evidence map›Paper›PMID 42285923›Full record

Trial reportSignal transduction and targeted therapy2026

Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation.

Jiajun Ding, Huimin Meng, Yidi Wang, Haoyi Zi, Mengxuan Li, He Chen, Cong Fan, Shuai Wang, Liying Zhang, Lei Shang and 3 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05558722 (Anlotinib Plus Chemotherapy as Neoadjuvant Treatment of High-risk, Early-stage Human Epidermal Growth Factor Receptor 2), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05558722 phase2active not recruitingnot on this map

Anlotinib Plus Chemotherapy as Neoadjuvant Treatment of High-risk, Early-stage Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer: A Prospective, Single-arm, Single-center, Phase II Clinical Study

TypeinterventionalSponsorXijing HospitalRan2022 to 2028Enrolled31ConditionsBreast Cancer Stage IIArmsAnlotinib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiajun Ding *Department of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Huimin Meng *Department of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Yidi Wang *Department of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Haoyi ZiDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Mengxuan LiDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
He ChenDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Cong FanDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Shuai WangDepartment of General Surgery, 986 Hospital, Xijing Hospital, Air Force Medical University, Xi'an, 710032, PR China.
Liying ZhangDepartment of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China.
Lei ShangDepartment of Health Statistics, Fourth Military Medical University, Xi'an, 710032, PR China.
Jing KongDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China. kongjing1119@163.com.
Jing FanDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China. jingfan@vip.163.com.
Ting WangDepartment of Thyroid, Breast, and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, PR China. ting_w100@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite being an option for high-risk or inoperable cases, existing neoadjuvant therapies for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer yield suboptimal pathological responses, necessitating novel strategies. This prospective, phase II ACNTBC trial (NCT05558722) investigated the efficacy and safety of combining anlotinib with chemotherapy as a neoadjuvant treatment for HR+/HER2- breast cancer. Enrolled patients received 5 cycles of anlotinib (12 mg qd, d1‒14; q3w) plus 6 cycles of nab-paclitaxel (200 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesIndolesNeoadjuvant TherapyQuinolinesAdultAgedCyclophosphamideDoxorubicinFemaleHumansMiddle AgedPaclitaxelProspective StudiesReceptors, EstrogenanlotinibCyclophosphamideDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIndolesPaclitaxelQuinolinesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID42285923
PMCPMC13263349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.